Navigation Links
Gene Study Throws Up New Targets for Leishmaniasis

Gene sleuths believe they may have identified potential chinks in the parasite that causes leishmaniasis, a disfiguring and sometimes fatal disease that afflicts some 12 million people around the world . Their comparison of three species of protozoa that cause most cases of leishmaniasis could be a boon for drug engineers, whose budgets for tackling this neglected disease are already slender.

British-led scientists compared the genetic code of Leishmania major, which causes the cutaneous form of leishmaniasis, with those of L. infantum and L. braziliensis, which cause the more dangerous, visceral form of the disease, also called kala-azar. What struck the researchers was that these parasites were very similar genetically, even though they cause very different types of disease.

Each genome has more than 8,000 genes, but only 200 of them differ across the three species. "The degree of similarity between these species was unexpected," said Deborah Smith, a professor at the University of York, northern England. "Perhaps only a few parasite genes are important in determining which type of disease develops after infection, and the host genome plays a major role in clinical outcome."

Another surprise was to find a small number of genes that have never been spotted before. Fellow investigator Chris Peacock described these novel genes as a "short cut" that could help the pharmaceutical quest. "Given their lack of similarity to human genes, they present a limited repertoire of potential targets for drug and vaccine development, allowing researchers to optimise the use of limited resources."

The Leishmania parasite is transmitted in the saliva of sandflies, who tuck in to a blood meal on humans, wild animals and dogs. Around 350 million people in 88 countries are "at risk" of the disease, whose incidence has risen sharply over the past decade, according to the Wellcome Trust Sanger Institute, a British medical research ch arity that led the genome comparison.

The frontline affordable drug, sodium stiboglucomate, marketed as Pentostam, is running into bad resistance problems, leaving many doctors with the option of more expensive treatment that, in the case of visceral leishmaniasis, can cost up to 150 dollars for a four-week course. Cutaneous and mucosal leishmaniasis results in painful, crater-like lesions on the skin.

Visceral leishmaniasis, which affects the spleen and liver, causing fever and weight loss, is fast becoming an opportunistic disease among people whose immune systems have been compromised by the AIDS virus. The study appears on Sunday in the journal Nature Genetics.


'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic ... has joined the revolutionary endoscopic practice under Dr. Datta. Patel is a Board ... Medicine. The patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is ...
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to May ... Medicine will host industry leaders for the annual spring Convention & Expo, called ... industry adapt to the issues currently affecting urgent care and on-demand healthcare. , ...
(Date:4/28/2017)... Diego, Ca (PRWEB) , ... April 28, 2017 , ... ... property management industry in the coastal communities. After Tina Howe joined the team, the ... and happy employees, honest services at affordable rates, and giving back to the San ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is pleased ... has 20+ years of experience within the beauty industry, ranging from marketing, retail ... of high-end cosmetic brands, retail brands and outlets in Canada and New York. ...
(Date:4/28/2017)... ... 28, 2017 , ... NuevaCare, a leading home care agency based in San ... Alto, is proud to announce information upgrades to its blog in the form of ... on topics such as home care (generally) as well as senior care and home ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
Breaking Medicine Technology: